Piramal Pharma Limited has announced an improved Environment, Social, and Governance (ESG) rating of 64 for the financial year 2024-25, as assessed by NSE Sustainability Ratings and Analytics. This score marks a notable increase from the previous rating of 61, reflecting the company’s ongoing dedication to sustainable development and responsible business practices. The assessment was conducted independently by the rating agency using publicly available information.
Rating Improvement and ESG Commitment
Piramal Pharma Limited continues to demonstrate progress in its sustainability journey. The latest report for the 2024-25 fiscal year confirms an ESG score of 64, up from 61 in the prior assessment. This upward trend underscores the company’s systematic efforts to integrate responsible operations into its core business strategy.
Independent Assessment Details
The rating was assigned by NSE Sustainability Ratings and Analytics Limited. It is important to note that this was an independent, voluntary exercise performed by the rating agency, meaning the company did not formally engage the agency for this specific evaluation. The score was derived entirely from data made available by the company in the public domain, ensuring transparency in how the organization is benchmarked against environmental and social governance standards.
Source: BSE
